| 2009 | Immunoglobulin D Multiple Myeloma: Clinical Presentation, Response to Therapy and Prognostic Factors in 75 Patients; An Analysis of the Korean Multiple Myeloma Working Party (KMMWP). | 문영철 | Meeting Abstract |
| 2009 | Induction Therapy with "3+7" Chemotherapy Plus ATRA Followed by Consolidations with Three Courses of Idarubicin Alone and Maintenance Therapy with ATRA in Newly Diagnosed Acute Promyelocytic Leukemia (APL) Has An Excellent Leukemia-Free Survival but Minimal Toxicity in Low and Intermediate Risk Groups | 성주명; 문영철 | Meeting Abstract |
| 2010 | Intensified 1st Cycle Rituximab (R) Plus 8(th) Cycles of R-CHOP (cyclophosphamide, adriamycin, vincristine, prednisolone) Chemotherapy In Patients with Advanced or Bulky CD20(+) Diffuse Large B-Cell Lymphoma (DLBCL); Open-Labelled, Multicenter Phase II CISL Study-Interim Analysis. | 문영철 | Meeting Abstract |
| 2023 | Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study | 문영철 | Article |
| 2020 | Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis | 문영철 | Article |
| 2023 | Long-Term Efficacy and Safety of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria and High Disease Burden: Real-World Data From Korea | 문영철 | Article |
| 2022 | Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia | 성주명; 문영철; 김대영; 박영훈 | Article |
| 2011 | Matched-Pair Analysis Comparing Outcomes of Second Autologous Stem Cell Transplantation and Chemotherapy As a Salvage Therapy in Patients with Multiple Myeloma Who Relapsed After Front-Line Autologous Stem Cell Transplantation | 문영철 | Meeting Abstract |
| 2011 | Nilotinib Combined with Multi-Agent Chemotherapy for Adult Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Interim Results of Korean Adult ALL Working Party Phase 2 Study | 문영철 | Meeting Abstract |
| 2015 | Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia | 문영철 | Article |
| 2023 | Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170) | 문영철 | Article |
| 2020 | Optimizing Preparative Regimen for Umbilical Cord Blood Transplantation in Adult Acute Leukemia Patients: Acute Lymphoblastic Leukemia Requires Myeloablative Conditioning but Not Acute Myeloid Leukemia | 문영철 | Article |
| 2016 | Preparation of 11-hexyloxy-9-undecenoic acid from crude castor oil hydrolysates by recombinant Escherichia coli expressing alcohol dehydrogenase and Baeyer-Villiger monooxygenase | 박진병 | Article |
| 2016 | Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome | 성주명; 문영철 | Article |
| 2023 | Propensity score matching analysis of perioperative outcomes including quality of life after multi-port vs. single port laparoscopic cholecystectomy: a nationwide prospective multicenter study in Korea | 이현국; 이희성 | Article |
| 2012 | Prospective Cohort Study with Risk-Adapted Central Nervous System (CNS) Evaluation in Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Analysis of Incidence and Risk Factors for Secondary CNS Involvement. | 문영철 | Meeting Abstract |
| 2020 | Safety and Feasibility of Robotic Reduced-Port Distal Pancreatectomy: a Multicenter Experience of a Novel Technique | 이희성 | Article |
| 2012 | Sequential High-Dose Dexamethasone and Response Adapted PAD (Bortezomib, Adriamycin, Dexamethasone) or VAD (Vincristine, Adriamycin, Dexamethasone) Chemotherapy Followed by High-Dose Therapy with ASCT for Newly Diagnosed Multiple Myeloma; Open-Labeled, Multicenter Phase 2 Study (KMM-94 Study)-Interim Analysis. | 문영철 | Meeting Abstract |
| 2011 | Sequential High-Dose Dexamethasone and Response Adapted PAD (Bortezomib, Adriamycin, Dexamethasone) or VAD (Vincristine, Adriamycin, Dexamethasone) Induction Chemotherapy Followed by High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma; Open-Labelled, Multicenter Phase 2 Study (KMM-94 Study)-Interim Analysis | 문영철 | Meeting Abstract |
| 2008 | Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (Bortezomib, Thalidomide, Dexamethasone) Induction Followed by High-Dose Therapy with Autologous Stem Cell Transplantation and Maintenance Treatment with Bortezomib for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase II Trial | 성주명 | Meeting Abstract |
| 2007 | Sequential VAD (vincristine, adriamycin, dexamethasone) and VTD (VELCADE (R), thalidomide, dexamethasone) induction followed by high-dose therapy with autologous stem cell transplantation and maintenance treatment with VELCADE for newly diagnosed multiple myeloma: Interim results of phase II trial | 성주명 | Meeting Abstract |
| 2014 | Symptom-oriented clinical detection versus routine imaging as a monitoring policy of relapse in patients with diffuse large B-cell lymphoma | 박상희 | Article |
| 2014 | The burden of nosocomial staphylococcus aureus bloodstream infection in South Korea: a prospective hospital-based nationwide study | 최희정 | Article |
| 2018 | The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma | 문영철 | Article |
| 2020 | The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study) | 문영철 | Article |
| 2007 | The equal activity of azacytidine in 4 risk groups of IPSS in MDS | 문영철 | Meeting Abstract |
| 2008 | Velcade (R), Thalidomide, Dexamethasone (VTD) Followed by Melphalan, Prednisone, Thalidomide (MPT) Maintenance as a First Line Treatment Demonstrates High Response Rates for High-Risk Patients with Multiple Myeloma (MM) Who Are Non-Transplant Candidates: Updated Results of Phase II Trial. | 성주명 | Meeting Abstract |
| 2007 | Velcade (R), thalidomide, dexamethasone (VTD) induction therapy followed by melphalan, prednisone, thalidomide (MPT) maintenance as a first line treatment for the patients (pts) with multiple myeloma (MM) who are non-transplant candidates: Early analysis from the Korean multiple myeloma working party | 성주명 | Meeting Abstract |
